PKC-IN-1

PKC-IN-1 is a potent, ATP-competitive and reversible inhibitor of conventional PKC enzymes with Kis of 5.3 and 10.4 nM for human PKCβ and PKCα, and IC50s of 2.3, 8.1, 7.6, 25.6, 57.5, 314, 808 nM for PKCα, PKCβI, PKCβII, PKCθ, PKCγ, PKC mu and PKCε, respectively.

Research Areas >> Inflammation/Immunology

Human PKCα:2.3 nM (IC50)

Human PKCβII:7.6 nM (IC50)

Human PKCβI:8.1 nM (IC50)

Human PKCθ:25.6 nM (IC50)

Human PKCγ:57.5 nM (IC50)

Human PKC mu:314 nM (IC50)

Human PKCε:808 nM (IC50)

Human PKCβ:5.3 nM (Ki)

Human PKCα:10.4 nM (Ki)

PKC-IN-1 (Compound A) is a potent, ATP-competitive and reversible of conventional PKC enzymes with Kis of 5.3 and 10.4 nM for human PKCβ and PKCα, and IC50s of 2.3, 8.1, 7.6, 25.6, 57.5, 314, 808 nM for PKCα, PKCβI, PKCβII, PKCθ, PKCγ, PKC mu and PKCε, respectively[1].

PKC-IN-1 (Compound A; 15 and 30 mg/kg, p.o., bid (twice a day)) dose-dependently and significantly reduces maximum EAE severity and end severity in autoimmune encephalitis (EAE) model in Lewis rats[1].

Rats[1] PKC-IN-1 is tested in the experimental autoimmune encephalitis (EAE) model in Lewis rats. EAE is induced by MBP69-88/CFA immunization and pertussis toxin injection in Lewis rats. PKC-IN-1 is prepared as an oral suspension and dosed orally, twice per day (BID) at three doses, 7.5 and 15 and 30 mg/kg for total daily doses of 15, 30 and 60 mg/kg. The efficacy is compared to animals that receive the positive control FTY720 dosed once per day at a dose of 0.5 mg/kg. The treatment starts on Day 8, when 48% of the rats have signs of EAE[1].

[1]. Michael Niesman, et al. Treatment of autoimmune disease. WO2015179847A1.

12-O-tetradecanoylphorbol-13-acetate | Staurosporine | Midostaurin | Go 6983 | Bisindolylmaleimide I (GF109203X) | Sotrastaurin | Ro-318220 | Chelerythrine chloride | Enzastaurin (LY317615) | Ruboxistaurin hydrochloride | Beta-Amyloid(1-40) | CGP60474 | Darovasertib (LXS-196) | (-)-Indolactam V | HA-100